PA
DNA icon

Parallel Advisors’s Ginkgo Bioworks DNA Stock Holding History

Parallel Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91K Sell
312
-126
-29% -$1.05K ﹤0.01% 3390
2025
Q4 		$3.64K Hold
438
– – ﹤0.01% 2946
2025
Q3 		$6.39K Sell
438
-36
-8% -$431 ﹤0.01% 2687
2025
Q2 		$5.33K Buy
474
+248
+110% +$1.92K ﹤0.01% 2721
2025
Q1 		$1.29K Buy
226
+56
+33% +$571 ﹤0.01% 3070
2024
Q4 		$1.67K Hold
170
– – ﹤0.01% 3017
2024
Q3 		$1.39K Sell
170
-23
-12% -$230 ﹤0.01% 2969
2024
Q2 		$2.58K Sell
193
-96
-33% -$2.86K ﹤0.01% 2730
2024
Q1 		$13.4K Buy
289
+10
+4% +$518 ﹤0.01% 2174
2023
Q4 		$18.8K Sell
279
-33
-11% -$2.02K ﹤0.01% 1987
2023
Q3 		$22.6K Buy
312
+3
+1% +$240 ﹤0.01% 1778
2023
Q2 		$23K Buy
309
+110
+55% +$6.51K ﹤0.01% 1783
2023
Q1 		$10.6K Sell
199
-62
-24% -$3.93K ﹤0.01% 2103
2022
Q4 		$17.6K Buy
261
+59
+29% +$5.43K ﹤0.01% 1766
2022
Q3 		$25K Buy
202
+32
+19% +$3.81K ﹤0.01% 1579
2022
Q2 		$16K Buy
+170
New +$20.7K ﹤0.01% 1758
2021
Q4 		– Sell
-63
Closed -$29K – 3133
2021
Q3 		$29K Buy
+63
New +$30.7K ﹤0.01% 1545

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors's DNA Position: Q1 2026 in Review

Parallel Advisors reduced its Ginkgo Bioworks (DNA) stake by 29% in Q1 2026, selling an estimated $1.05K and leaving 312 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #3390.

Parallel Advisors first reported a position in DNA in Q3 2021 and has held it in 17 quarters since. The position peaked at $29K in Q3 2021. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Parallel Advisors held 312 shares of Ginkgo Bioworks worth $1.91K as of Q1 2026.
  • Parallel Advisors sold 126 Ginkgo Bioworks shares in Q1 2026, an estimated $1.05K.
  • Ginkgo Bioworks made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3390 holding.
  • Parallel Advisors first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 17 quarters since.
  • Parallel Advisors's Ginkgo Bioworks position peaked at $29K in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.